Business Context and Reporting Period
Company: Deckers Outdoor Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1997
Business Overview: The company designs, markets, and distributes outdoor footwear under the Teva(R), Simple(R), and Ugg(R) brands. The first quarter is a peak season for Teva(R) sales.
Key Financial Metrics
| Metric | Q1 1997 | Q1 1996 |
|---|---|---|
| Net Sales | $34,441,000 | $28,772,000 |
| Gross Profit | $14,950,000 | $12,590,000 |
| Gross Margin | 43.4% | 43.8% |
| Net Earnings | $1,990,000 | $1,479,000 |
| Earnings Per Share (Diluted) | $0.22 | $0.16 |
| Operating Cash Flow | ($1,418,000) | $4,373,000 |
| Cash and Equivalents (End of Period) | $1,481,000 | $3,596,000 |
| Total Debt (Current + Long-term) | $12,890,000 | N/A |
| Working Capital | $44,205,000 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 19.7% year-over-year, driven primarily by a 30.4% increase in Teva(R) sales and a 15.3% increase in Simple(R) sales. International sales grew 2.9% but represented a smaller percentage of total sales (27.0% vs. 31.4%).
- Profitability: Net earnings rose 34.6% to $1.99 million. Gross margin decreased slightly to 43.4% due to a $500,000 charge for the closure of the California manufacturing facility.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 9.4% but decreased as a percentage of sales (31.3% vs. 34.2%) due to the non-recurrence of certain Ugg operating expenses from the prior year.
- Cash Flow: Operating cash flow turned negative ($1.42 million outflow) compared to a $4.37 million inflow in the prior year. This was primarily due to a $11.3 million increase in trade accounts receivable resulting from late-quarter Teva(R) sales.
- Inventory: Inventory levels decreased 14.4% to $21.3 million, reflecting the shift in sales timing.
Guidance, Outlook, and Risks
- Product Outlook: Management expects Simple(R) sales to be flat or slightly higher in 1997 compared to 1996. Ugg(R) sales are expected to be slightly lower than the previous year's $14.8 million. These declines are anticipated to be offset by continued growth in the Teva(R) line.
- Seasonality: Results are highly seasonal. Teva(R) peaks in Q1/Q2, Simple(R) in Q3, and Ugg(R) in Q4. A shift in consumer preferences could lead to obsolete inventory.
- Liquidity: The company maintains a $25 million revolving credit facility with approximately $9.6 million available as of March 31, 1997. Management believes internal funds and available borrowings are sufficient for working capital needs.
- Legal Contingency: Former shareholders of Ugg Holdings have demanded arbitration regarding acquisition payments. The company disputes these claims and has filed counterclaims. The arbitration date is pending.
- Accounting Changes: The company will adopt FAS 128 (Earnings per Share) in Q4 1997, requiring dual presentation of Basic and Diluted EPS, though no material impact is expected.
Investor Verification Checklist
- Receivables Quality: Verify the collectability of the $28.9 million in trade receivables, which increased 62.2% quarter-over-quarter.
- Factory Closure Impact: Confirm the full financial impact of the California facility closure and any subsequent cost savings realized in Q2.
- Ugg Arbitration: Monitor the status of the arbitration with former Ugg shareholders regarding potential additional acquisition payments.
- Seasonal Sales Mix: Track Q2 Teva(R) sales performance to ensure it meets expectations to offset anticipated declines in Simple(R) and Ugg(R) lines later in the year.
- Debt Covenants: Review compliance with financial ratios required by the $25 million revolving credit facility.